financetom
Business
financetom
/
Business
/
Paycom Software Q2 Non-GAAP Earnings Steady, Revenue Rises; Share Buyback Plan Boosted
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Paycom Software Q2 Non-GAAP Earnings Steady, Revenue Rises; Share Buyback Plan Boosted
Jul 31, 2024 3:21 PM

05:57 PM EDT, 07/31/2024 (MT Newswires) -- Paycom Software ( PAYC ) reported Q2 non-GAAP earnings late Wednesday of $1.62 per diluted share, flat from a year earlier.

Analysts polled by Capital IQ expected $1.60.

Revenue for the quarter ended June 30 was $437.5 million, compared with $401.1 million a year earlier. Analysts surveyed by Capital IQ expected $436.4 million.

The company expects Q3 revenue ranging from $444 million to $449 million. Analysts forecast $448.4 million.

For full year 2024, the company expects revenue of $1.86 billion to $1.88 billion. It previously projected $1.86 billion to $1.89 billion. Analysts are looking for $1.87 billion.

The company's board increased its share buyback plan to $1.5 billion, from about $676 million previously available for repurchases, and extended it through Aug. 15, 2026.

Price: 165.70, Change: -1.09, Percent Change: -0.65

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Upstream Bio raises $255 mln in US IPO
Upstream Bio raises $255 mln in US IPO
Oct 10, 2024
Oct 10 (Reuters) - Upstream Bio, which is developing treatments for some respiratory disorders, said on Thursday it had raised $255 million in its initial public offering in the United States. The drug developer joins a swath of biotech companies rushing towards a stock market listing as a long-awaited policy easing cycle begins. September was the busiest month for healthcare...
Kaiser Permanente-backed biopharma CAMP4 raises $75 mln in US IPO
Kaiser Permanente-backed biopharma CAMP4 raises $75 mln in US IPO
Oct 10, 2024
Oct 10 (Reuters) - CAMP4 Therapeutics, a biopharmaceutical firm backed by healthcare giant Kaiser Permanente on Thursday raised $75 million after pricing its U.S. initial public offering (IPO). CAMP4 sold 6.82 million shares in the IPO for $11 per share, the company said in a statement. (Reporting by Pretish M J in Bengaluru) ...
WeightWatchers adds compounded version of Novo's obesity drug to weight-loss program
WeightWatchers adds compounded version of Novo's obesity drug to weight-loss program
Oct 10, 2024
Oct 8 (Reuters) - WeightWatchers said on Tuesday it is adding a compounded version of Novo Nordisk's obesity drug Wegovy to its weight-management programs. ...
What's Going On With Ambow Education Shares Premarket Tuesday?
What's Going On With Ambow Education Shares Premarket Tuesday?
Oct 10, 2024
Ambow Education Holding Ltd. ( AMBO ) shares, which had a tremendous run yesterday, are trading lower premarket today. On Monday, Ambow Education ( AMBO ) entered into a $1.3 million annual renewable licensing agreement with Inspiring Futures Pte. LTD. This non-exclusive deal permits the production and international distribution of the HybriU AI UniBox and the comprehensive HybriU educational solution....
Copyright 2023-2026 - www.financetom.com All Rights Reserved